Weihai Weigao Blood Purified Product Co., Ltd. announced that it expects to receive CNY 100 million in funding from Nikkiso Co., Ltd.
December 03, 2017
Share
Weihai Weigao Blood Purified Product Co., Ltd. announced that it has entered into a capital increase agreement with new investor Nikkiso Co., Ltd. (TSE:6376) for private placement of common shares for gross proceeds of CNY 100 million on December 4, 2017. Pursuant to closing, Nikkiso Co., Ltd. (TSE:6376) will hold 5% stake in the company.
NIKKISO CO.,LTD. is a Japan-based company principally engaged in the manufacture and sale of industrial pumps, precision equipment and blood related products, among others. The Company operates in two business segments. Industrial Business segment conducts industrial business including the manufacture, sale and maintenance of industrial special pumps, as well as liquefied gas & industrial gas related equipment and devices. The Segment is also involved in precision equipment business, aerospace business and deep ultraviolet light emitting diode (LED) business. Medical Business segmentâs products are dialysis-related products including hemodialysis and peritoneal dialysis, such as artificial dialysis machines, dialyzers, blood circuits, and powder-type dialysis agents. The Segment also manufactures, sells and maintains products and medicines related to CRRT (acute blood purification therapy), artificial pancreas devices that manage blood glucose, and energy devices for microwave surgery.
NIKKISO CO., LTD. 
